Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study

Nita G. Forouhi; Albert Koulman; Stephen J. Sharp; Fumiaki Imamura; Janine Kroger; Matthias B. Schulze; Francesca L. Crowe; Jose Maria Huerta; Marcela Guevara; Joline W. J. Beulens; Geertruida J. van Woudenbergh; Laura Wang; Keith Summerhill; Julian L. Griffin; Edith J. M. Feskens; Pilar Amiano; Heiner Boeing; Francoise Clavel-Chapelon; Laureen Dartois; Guy Fagherazzi; Paul W. Franks; Carlos Gonzalez; Marianne Uhre Jakobsen; Rudolf Kaaks; Timothy J. Key; Kay-Tee Khaw; Tilman Kuhn; Amalia Mattiello; Peter M. Nilsson; Kim Overvad; Valeria Pala; Domenico Palli; J. Ramon Quiros; Olov Rolandsson; Nina Roswall; Carlotta Sacerdote; Mara-Jose Sanchez; Nadia Slimani; Annemieke M. W. Spijkerman; Anne Tjonneland; Maria-Jose Tormo; Rosario Tumino; Daphne L. van der A; Yvonne T. van der Schouw; Claudia Langenberg; Elio Riboli; Nicholas J. Wareham

doi:10.1016/S2213-8587(14)70146-9

Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study

Nita G. Forouhi, Albert Koulman, Stephen J. Sharp, Fumiaki Imamura, Janine Kroger, Matthias B. Schulze, Francesca L. Crowe, Jose Maria Huerta, Marcela Guevara, Joline W. J. Beulens, Geertruida J. van Woudenbergh, Laura Wang, Keith Summerhill, Julian L. Griffin, Edith J. M. Feskens, Pilar Amiano, Heiner Boeing, Francoise Clavel-Chapelon, Laureen Dartois, Guy FagherazziPaul W. Franks, Carlos Gonzalez, Marianne Uhre Jakobsen, Rudolf Kaaks, Timothy J. Key, Kay-Tee Khaw, Tilman Kuhn, Amalia Mattiello, Peter M. Nilsson, Kim Overvad, Valeria Pala, Domenico Palli, J. Ramon Quiros, Olov Rolandsson, Nina Roswall, Carlotta Sacerdote, Mara-Jose Sanchez, Nadia Slimani, Annemieke M. W. Spijkerman, Anne Tjonneland, Maria-Jose Tormo, Rosario Tumino, Daphne L. van der A, Yvonne T. van der Schouw, Claudia Langenberg, Elio Riboli, Nicholas J. Wareham

Aarhus University

Research output: Contribution to journal › Journal article › Research › peer-review

147 Downloads (Pure)

Abstract

Background: Conflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. Methods: The EPIC-InterAct case-cohort study includes 12 403 people with incident type 2 diabetes and a representative subcohort of 16 154 individuals who were selected from a cohort of 340 234 European participants with 3 . 99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis. Findings: SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14: 0 [myristic acid], 16: 0 [palmitic acid], and 18: 0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1.15 [95% CI 1.09-1.22], palmitic acid 1.26 [1.15-1.37], and stearic acid 1.06 [1.00-1.13]). By contrast, measured odd-chain SFAs (15: 0 [pentadecanoic acid] and 17: 0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0.79 [0.73-0.85] for pentadecanoic acid and 0.67 [0.63-0.71] for heptadecanoic acid), as were measured longer-chain SFAs (20: 0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0.72 to 0.81 (95% CIs ranging between 0.61 and 0.92). Our findings were robust to a range of sensitivity analyses. Interpretation: Different individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed.

Original language	English
Journal	Lancet Diabetes and Endocrinology
Volume	2
Issue number	10
Pages (from-to)	810-818
Number of pages	9
ISSN	2213-8595
DOIs	https://doi.org/10.1016/S2213-8587(14)70146-9
Publication status	Published - 2014
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-8587(14)70146-9

1 s2Final published version, 297 KB

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study'. Together they form a unique fingerprint.

Cite this

Forouhi, N. G., Koulman, A., Sharp, S. J., Imamura, F., Kroger, J., Schulze, M. B., Crowe, F. L., Huerta, J. M., Guevara, M., Beulens, J. W. J., van Woudenbergh, G. J., Wang, L., Summerhill, K., Griffin, J. L., Feskens, E. J. M., Amiano, P., Boeing, H., Clavel-Chapelon, F., Dartois, L., ... Wareham, N. J. (2014). Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study. Lancet Diabetes and Endocrinology, 2(10), 810-818. https://doi.org/10.1016/S2213-8587(14)70146-9

@article{ccf285c1a05040de9388fb28f72af28c,

title = "Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study",

abstract = "Background: Conflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. Methods: The EPIC-InterAct case-cohort study includes 12 403 people with incident type 2 diabetes and a representative subcohort of 16 154 individuals who were selected from a cohort of 340 234 European participants with 3 . 99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis. Findings: SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14: 0 [myristic acid], 16: 0 [palmitic acid], and 18: 0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1.15 [95% CI 1.09-1.22], palmitic acid 1.26 [1.15-1.37], and stearic acid 1.06 [1.00-1.13]). By contrast, measured odd-chain SFAs (15: 0 [pentadecanoic acid] and 17: 0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0.79 [0.73-0.85] for pentadecanoic acid and 0.67 [0.63-0.71] for heptadecanoic acid), as were measured longer-chain SFAs (20: 0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0.72 to 0.81 (95% CIs ranging between 0.61 and 0.92). Our findings were robust to a range of sensitivity analyses. Interpretation: Different individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed.",

author = "Forouhi, {Nita G.} and Albert Koulman and Sharp, {Stephen J.} and Fumiaki Imamura and Janine Kroger and Schulze, {Matthias B.} and Crowe, {Francesca L.} and Huerta, {Jose Maria} and Marcela Guevara and Beulens, {Joline W. J.} and {van Woudenbergh}, {Geertruida J.} and Laura Wang and Keith Summerhill and Griffin, {Julian L.} and Feskens, {Edith J. M.} and Pilar Amiano and Heiner Boeing and Francoise Clavel-Chapelon and Laureen Dartois and Guy Fagherazzi and Franks, {Paul W.} and Carlos Gonzalez and Jakobsen, {Marianne Uhre} and Rudolf Kaaks and Key, {Timothy J.} and Kay-Tee Khaw and Tilman Kuhn and Amalia Mattiello and Nilsson, {Peter M.} and Kim Overvad and Valeria Pala and Domenico Palli and Quiros, {J. Ramon} and Olov Rolandsson and Nina Roswall and Carlotta Sacerdote and Mara-Jose Sanchez and Nadia Slimani and Spijkerman, {Annemieke M. W.} and Anne Tjonneland and Maria-Jose Tormo and Rosario Tumino and {van der A}, {Daphne L.} and {van der Schouw}, {Yvonne T.} and Claudia Langenberg and Elio Riboli and Wareham, {Nicholas J.}",

note = "{\textcopyright} Forouhi et al. Open Access article distributed under the terms of CC BY. ",

year = "2014",

doi = "10.1016/S2213-8587(14)70146-9",

language = "English",

volume = "2",

pages = "810--818",

journal = "Lancet Diabetes and Endocrinology",

issn = "2213-8595",

publisher = "Elsevier",

number = "10",

}

Forouhi, NG, Koulman, A, Sharp, SJ, Imamura, F, Kroger, J, Schulze, MB, Crowe, FL, Huerta, JM, Guevara, M, Beulens, JWJ, van Woudenbergh, GJ, Wang, L, Summerhill, K, Griffin, JL, Feskens, EJM, Amiano, P, Boeing, H, Clavel-Chapelon, F, Dartois, L, Fagherazzi, G, Franks, PW, Gonzalez, C, Jakobsen, MU, Kaaks, R, Key, TJ, Khaw, K-T, Kuhn, T, Mattiello, A, Nilsson, PM, Overvad, K, Pala, V, Palli, D, Quiros, JR, Rolandsson, O, Roswall, N, Sacerdote, C, Sanchez, M-J, Slimani, N, Spijkerman, AMW, Tjonneland, A, Tormo, M-J, Tumino, R, van der A, DL, van der Schouw, YT, Langenberg, C, Riboli, E & Wareham, NJ 2014, 'Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study', Lancet Diabetes and Endocrinology, vol. 2, no. 10, pp. 810-818. https://doi.org/10.1016/S2213-8587(14)70146-9

Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study: the EPIC-InterAct case-cohort study. / Forouhi, Nita G.; Koulman, Albert; Sharp, Stephen J. et al.
In: Lancet Diabetes and Endocrinology, Vol. 2, No. 10, 2014, p. 810-818.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study

T2 - the EPIC-InterAct case-cohort study

AU - Forouhi, Nita G.

AU - Koulman, Albert

AU - Sharp, Stephen J.

AU - Imamura, Fumiaki

AU - Kroger, Janine

AU - Schulze, Matthias B.

AU - Crowe, Francesca L.

AU - Huerta, Jose Maria

AU - Guevara, Marcela

AU - Beulens, Joline W. J.

AU - van Woudenbergh, Geertruida J.

AU - Wang, Laura

AU - Summerhill, Keith

AU - Griffin, Julian L.

AU - Feskens, Edith J. M.

AU - Amiano, Pilar

AU - Boeing, Heiner

AU - Clavel-Chapelon, Francoise

AU - Dartois, Laureen

AU - Fagherazzi, Guy

AU - Franks, Paul W.

AU - Gonzalez, Carlos

AU - Jakobsen, Marianne Uhre

AU - Kaaks, Rudolf

AU - Key, Timothy J.

AU - Khaw, Kay-Tee

AU - Kuhn, Tilman

AU - Mattiello, Amalia

AU - Nilsson, Peter M.

AU - Overvad, Kim

AU - Pala, Valeria

AU - Palli, Domenico

AU - Quiros, J. Ramon

AU - Rolandsson, Olov

AU - Roswall, Nina

AU - Sacerdote, Carlotta

AU - Sanchez, Mara-Jose

AU - Slimani, Nadia

AU - Spijkerman, Annemieke M. W.

AU - Tjonneland, Anne

AU - Tormo, Maria-Jose

AU - Tumino, Rosario

AU - van der A, Daphne L.

AU - van der Schouw, Yvonne T.

AU - Langenberg, Claudia

AU - Riboli, Elio

AU - Wareham, Nicholas J.

PY - 2014

Y1 - 2014

N2 - Background: Conflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. Methods: The EPIC-InterAct case-cohort study includes 12 403 people with incident type 2 diabetes and a representative subcohort of 16 154 individuals who were selected from a cohort of 340 234 European participants with 3 . 99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis. Findings: SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14: 0 [myristic acid], 16: 0 [palmitic acid], and 18: 0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1.15 [95% CI 1.09-1.22], palmitic acid 1.26 [1.15-1.37], and stearic acid 1.06 [1.00-1.13]). By contrast, measured odd-chain SFAs (15: 0 [pentadecanoic acid] and 17: 0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0.79 [0.73-0.85] for pentadecanoic acid and 0.67 [0.63-0.71] for heptadecanoic acid), as were measured longer-chain SFAs (20: 0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0.72 to 0.81 (95% CIs ranging between 0.61 and 0.92). Our findings were robust to a range of sensitivity analyses. Interpretation: Different individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed.

AB - Background: Conflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. Methods: The EPIC-InterAct case-cohort study includes 12 403 people with incident type 2 diabetes and a representative subcohort of 16 154 individuals who were selected from a cohort of 340 234 European participants with 3 . 99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis. Findings: SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14: 0 [myristic acid], 16: 0 [palmitic acid], and 18: 0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1.15 [95% CI 1.09-1.22], palmitic acid 1.26 [1.15-1.37], and stearic acid 1.06 [1.00-1.13]). By contrast, measured odd-chain SFAs (15: 0 [pentadecanoic acid] and 17: 0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0.79 [0.73-0.85] for pentadecanoic acid and 0.67 [0.63-0.71] for heptadecanoic acid), as were measured longer-chain SFAs (20: 0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0.72 to 0.81 (95% CIs ranging between 0.61 and 0.92). Our findings were robust to a range of sensitivity analyses. Interpretation: Different individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed.

U2 - 10.1016/S2213-8587(14)70146-9

DO - 10.1016/S2213-8587(14)70146-9

M3 - Journal article

SN - 2213-8595

VL - 2

SP - 810

EP - 818

JO - Lancet Diabetes and Endocrinology

JF - Lancet Diabetes and Endocrinology

IS - 10

ER -